X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
D | 2023-11-04 | KROS | Regnante Keith | CFO | S - Sale+OE | $45.29 | -40,000 | 0 | -100% | -$1,811,600 | |||||
DM | 2023-06-08 | KROS | Regnante Keith | CFO | S - Sale+OE | $46.61 | -40,000 | 0 | -100% | -$1,864,239 | |||||
2020-04-13 | KROS | Knowles Julius | Dir | P - Purchase | $20.98 | +1,191 | 575,492 | 0% | +$24,987 | ||||||
D | 2022-07-15 | KROS | Lachey Jennifer | Chief Scientific Officer | S - Sale+OE | $30.00 | -46,034 | 95,100 | -33% | -$1,381,020 | |||||
D | 2022-07-13 | KROS | Lachey Jennifer | Chief Scientific Officer | S - Sale+OE | $30.00 | -1,916 | 95,100 | -2% | -$57,480 | |||||
D | 2022-05-11 | KROS | Lachey Jennifer | Chief Scientific Officer | S - Sale+OE | $41.90 | -5,300 | 85,700 | -6% | -$222,050 | |||||
D | 2022-04-11 | KROS | Lachey Jennifer | Chief Scientific Officer | S - Sale+OE | $62.77 | -5,300 | 85,700 | -6% | -$332,705 | |||||
D | 2022-04-06 | KROS | Rovaldi Christopher | COO | S - Sale+OE | $65.00 | -1,728 | 0 | -100% | -$112,320 | |||||
D | 2022-04-04 | KROS | Lachey Jennifer | Chief Scientific Officer | S - Sale+OE | $60.00 | -7,950 | 85,700 | -8% | -$477,000 | |||||
D | 2022-04-01 | KROS | Rovaldi Christopher | COO | S - Sale+OE | $57.49 | -864 | 0 | -100% | -$49,675 |
A | Amended filing |
D | Derivative transaction in filing (usually option exercise) |
E | Error detected in filing |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |